Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.

SG&A Expenses: BioMarin vs. BioCryst - A Decade of Change

__timestampBioCryst Pharmaceuticals, Inc.BioMarin Pharmaceutical Inc.
Wednesday, January 1, 20147461000302156000
Thursday, January 1, 201513047000402271000
Friday, January 1, 201611253000476593000
Sunday, January 1, 201713933000554336000
Monday, January 1, 201829514000604353000
Tuesday, January 1, 201937121000680924000
Wednesday, January 1, 202067929000737669000
Friday, January 1, 2021118818000759375000
Saturday, January 1, 2022159371000854009000
Sunday, January 1, 2023213894000937300000
Monday, January 1, 20241009025000
Loading chart...

Unlocking the unknown

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining financial health. BioMarin Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses from 2014 to 2023. BioMarin's expenses have consistently been higher, peaking at approximately $937 million in 2023, reflecting a steady growth of around 210% over the decade. In contrast, BioCryst's expenses, while significantly lower, have surged by nearly 280%, reaching about $214 million in 2023. This divergence highlights BioMarin's expansive operational scale compared to BioCryst's more conservative approach. Understanding these trends offers insights into each company's strategic priorities and market positioning. As the biotech industry evolves, monitoring such financial metrics will be key to predicting future growth trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025